Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
about
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model.The potential and perils of observational studies.Paclitaxel inhibits breast cancer metastasis via suppression of Aurora kinase-mediated cofilin-1 activity.A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study
P2860
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Paclitaxel plus bevacizumab or ...... national observational study.
@en
Paclitaxel plus bevacizumab or ...... national observational study.
@nl
type
label
Paclitaxel plus bevacizumab or ...... national observational study.
@en
Paclitaxel plus bevacizumab or ...... national observational study.
@nl
prefLabel
Paclitaxel plus bevacizumab or ...... national observational study.
@en
Paclitaxel plus bevacizumab or ...... national observational study.
@nl
P2093
P2860
P356
P1433
P1476
Paclitaxel plus bevacizumab or ...... r national observational study
@en
P2093
A Goncalves
B Asselain
C Cailliot
C Courtinard
C Jouannaud
P2860
P304
P356
10.1093/ANNONC/MDW260
P577
2016-07-19T00:00:00Z